<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit Financial
         Document created using Broadridge PROfile 23.5.1.5152
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: center; font-weight: bold;">As filed with the Securities and Exchange Commission on June 27, 2023</div>
    <div style="margin: 0px 27pt 0px 0px; font-weight: bold; text-align: right;">Registration No. 333-</div>
    <div>
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div style="text-align: center; font-size: 14pt; font-weight: bold;">UNITED STATES</div>
    <div style="text-align: center; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>
    <div>&#160;
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    <div style="text-align: center; font-size: 18pt; font-weight: bold;">FORM S-8</div>
    <div style="text-align: center; font-weight: bold;">REGISTRATION STATEMENT</div>
    <div style="text-align: center; font-style: italic; font-weight: bold;">UNDER</div>
    <div style="text-align: center; font-style: italic; font-weight: bold;">THE SECURITIES ACT OF 1933</div>
    <div>&#160;
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    <div>&#160;</div>
    <div style="text-align: center; font-size: 24pt; font-weight: bold;">NANOBIOTIX S.A.</div>
    <div style="text-align: center; font-weight: bold;">(Exact name of registrant as specified in its charter)</div>
    <div>&#160;
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    <div> <br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z7264d682c26a4d71acb92f7d97b97c13">

        <tr>
          <td style="width: 49.8%; vertical-align: bottom;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">France</div>
          </td>
          <td style="width: 50.2%; vertical-align: bottom;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Not applicable</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.8%; vertical-align: bottom;">
            <div style="text-align: center; font-weight: bold;">(State or other jurisdiction of incorporation or organization)</div>
          </td>
          <td style="width: 50.2%; vertical-align: bottom;">
            <div style="text-align: center; font-weight: bold;">(I.R.S. employer identification No.)</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">60 rue de Wattignies</div>
    <div style="text-align: center; font-weight: bold;">75012 Paris, France</div>
    <div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(Address of Principal Executive Offices)(Zip Code)</div>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">2023 Free Share Plan</div>
    <div style="text-align: center; font-weight: bold;">&#160;(Full title of the plans)</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">Nanobiotix Corporation</div>
    <div style="text-align: center; font-weight: bold;">Attn: Bart Van Rhijn</div>
    <div style="text-align: center; font-weight: bold;">245 Main Street</div>
    <div style="text-align: center; font-weight: bold;">Cambridge, Massachusetts 02142</div>
    <div style="text-align: center; font-weight: bold;">+1 617 712 1568</div>
    <div style="text-align: center; font-weight: bold;">(Name and address of agent for service) (Telephone number, including area code, of agent for service)</div>
    <div>&#160;
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    <div> <br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z232f375201fd46e38f884b8ab4825854">

        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div style="text-align: center; font-style: italic;">Copies to:</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: bottom;">
            <div style="text-align: center; font-weight: bold;">Peter E. Devlin</div>
            <div style="text-align: center; font-weight: bold;">Shoshana E. Litt</div>
            <div style="text-align: center; font-weight: bold;">Jones Day</div>
            <div style="text-align: center; font-weight: bold;">250 Vesey Street</div>
            <div style="text-align: center; font-weight: bold;">New York, New York 10281</div>
            <div style="text-align: center; font-weight: bold;">+1 212 326 3939</div>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">Renaud Bonnet</div>
            <div style="text-align: center; font-weight: bold;">Jean-Gabriel Griboul</div>
            <div style="text-align: center; font-weight: bold;">Jones Day</div>
            <div style="text-align: center; font-weight: bold;">2 rue Saint-Florentin</div>
            <div style="text-align: center; font-weight: bold;">75001 Paris, France</div>
            <div style="text-align: center; font-weight: bold;">+33 1 56 59 39 39</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div>Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated
      filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</div>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zd9c27df00ade40b2a06d0a60bafffdee">

        <tr>
          <td style="width: 18%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">Large accelerated filer</div>
          </td>
          <td style="width: 6.64%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);">&#9744;</div>
          </td>
          <td style="width: 43%; vertical-align: top;"><br>
          </td>
          <td style="width: 25.39%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">Accelerated filer</div>
          </td>
          <td style="width: 6.64%; vertical-align: bottom; text-align: center;">&#9746;</td>
        </tr>
        <tr>
          <td style="width: 18%; vertical-align: top;">&#160;</td>
          <td style="width: 6.64%; vertical-align: bottom; text-align: center;">&#160;</td>
          <td style="width: 43%; vertical-align: top;"><br>
          </td>
          <td style="width: 25.39%; vertical-align: top;">&#160;</td>
          <td style="width: 6.64%; vertical-align: bottom; text-align: center;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 18%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">Non-accelerated filer</div>
          </td>
          <td style="width: 6.64%; vertical-align: bottom; text-align: center;">&#9744;</td>
          <td style="width: 43%; vertical-align: top;"><br>
          </td>
          <td style="width: 25.39%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">Smaller reporting company</div>
          </td>
          <td style="width: 6.64%; vertical-align: bottom; text-align: center;">&#9744;</td>
        </tr>
        <tr>
          <td style="width: 18%; vertical-align: top;"><br>
          </td>
          <td style="width: 6.64%; vertical-align: bottom; text-align: center;"><br>
          </td>
          <td style="width: 43%; vertical-align: top;"><br>
          </td>
          <td style="width: 25.39%; vertical-align: top;">&#160;</td>
          <td style="width: 6.64%; vertical-align: bottom; text-align: center;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 18%; vertical-align: top;"><br>
          </td>
          <td style="width: 6.64%; vertical-align: bottom; text-align: center;"><br>
          </td>
          <td style="width: 43%; vertical-align: top;"><br>
          </td>
          <td style="width: 25.39%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">Emerging growth company</div>
          </td>
          <td style="width: 6.64%; vertical-align: bottom; text-align: center;">&#9746;</td>
        </tr>

    </table>
    <div>&#160;
      <div style="color: rgb(0, 0, 0);">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to
        Section 7(a)(2)(B) of the Securities Act. &#9744;</div>
    </div>
    <div>&#160;</div>
    <div>
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; font-weight: bold;">PART I</div>
    <div>
      <div>&#160;</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS</div>
    </div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;">The information specified in Part I of Form S-8 is omitted from this Registration Statement in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the &#8220;<font style="font-weight: bold; font-style: italic;">Securities Act</font>&#8221;) and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the plans covered by this Registration
      Statement as specified by Rule 428(b)(1) under the Securities Act.</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">PART II</div>
    <div>&#160;</div>
    <div>
      <div style="text-align: center; color: #000000; font-weight: bold;">INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</div>
    </div>
    <div>&#160;</div>
    <div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z664e3f7b2edc4ef88d0d7054a8a3e483" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">

          <tr style="vertical-align: top;">
            <td style="text-align: right; vertical-align: top; width: 45pt;">
              <div style="text-align: left;"><font style="font-weight: bold;">ITEM 3.</font></div>
            </td>
            <td style="text-align: left; vertical-align: top; width: auto;">
              <div><font style="font-weight: bold;">INCORPORATION OF DOCUMENTS BY REFERENCE</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">The following documents filed by Nanobiotix S.A. (the &#8220;<font style="font-weight: bold; font-style: italic;">Registrant</font>&#8221;) with the U.S. Securities and Exchange Commission (the &#8220;<font style="font-weight: bold; font-style: italic;">Commission</font>&#8221;) are incorporated by reference into this Registration Statement:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">(a)</font>&#160;&#160; the Registrant&#8217;s Annual Report on Form 20-F (File No. 001-39777) for the year ended December 31, 2022, filed with the Commission pursuant to Section 13
      or 15(d) of the Securities Exchange Act of 1934, as amended (the &#8220;<font style="font-weight: bold; font-style: italic;">Exchange Act</font>&#8221;) on <a href="https://www.sec.gov/Archives/edgar/data/1760854/000176085423000005/nbx-20221231.htm">April 24,
        2023</a>, which contains audited financial statements for the Registrant&#8217;s latest fiscal year for which such statements have been filed;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">(b)</font>&#160; the Registrant&#8217;s Reports on Form 6-K (File No. 001-39777) that are furnished to the Commission and that are identified in such form as being incorporated
      by reference, since the end of the fiscal year covered by the Registrant&#8217;s Annual Report on Form 20-F referred to in (a) above; and</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">(c)</font>&#160;&#160; the descriptions of the Registrant&#8217;s American Depositary Shares and Ordinary Shares contained in the Registrant&#8217;s Registration Statement on Form 8-A
      filed with the Commission on <a href="https://www.sec.gov/Archives/edgar/data/1760854/000114036120027625/nt1009390x10_8a12b.htm">December 8, 2020</a> (File No. 001-39777) under the Exchange Act, including any amendment or report filed for the
      purpose of updating such description, including the description of the Registrant&#8217;s securities included as <a href="https://www.sec.gov/Archives/edgar/data/1760854/000176085423000005/a2022xex23xnanobiotixx20xf.htm">Exhibit 2.3</a> to the
      Registrant&#8217;s Annual Report on Form 20-F filed with the Commission on April 24, 2023.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior
      to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all such securities then remaining unsold, shall be deemed to be incorporated by
      reference herein and to be a part of this Registration Statement from the date of filing of such reports and documents. Any statement contained in this Registration Statement, in an amendment hereto or in a document incorporated or deemed to be
      incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed amendment to this Registration Statement or in any
      document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this
      Registration Statement.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">Information subsequently furnished on Form 6-K shall not be deemed incorporated herein by reference unless such Form 6-K expressly provides to the contrary.</div>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zab0c58f5dc504999b493ce5a3cd4029d">

        <tr>
          <td style="width: 45pt; vertical-align: top; font-weight: bold;">ITEM 4.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">DESCRIPTION OF SECURITIES</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div>Not applicable.</div>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z775933b1d5414552a43c2823c2dc7ba6">

        <tr>
          <td style="width: 45pt; vertical-align: top; font-weight: bold;">ITEM 5.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">INTERESTS OF NAMED EXPERTS AND COUNSEL</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div>Not applicable.</div>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z10bb267a6d2445e297d3d05f775b8f31">

        <tr>
          <td style="width: 45pt; vertical-align: top; font-weight: bold;">ITEM 6.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">INDEMNIFICATION OF DIRECTORS AND OFFICERS</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="text-indent: 36pt;">Under French law, provisions in the By-laws that limit the liability of directors and officers are ineffective. However, French law allows <font style="font-style: italic;">soci&#233;t&#233;s anonymes</font> to contract for and
      maintain liability insurance against civil liabilities incurred by any of their directors and officers involved in a third-party action, <font style="font-style: italic;">provided</font> that they acted in good faith and within their capacities as
      directors or officers of the company. Criminal liability cannot be indemnified under French law, whether directly by the company or through liability insurance. Such rules apply to executive and supervisory board members.</div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;">The Registrant has obtained and maintains customary liability insurance coverage for our supervisory board members and executive board members, including insurance against liability under the Securities Act.</div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to the Registrant&#8217;s directors, officers and controlling persons, the Registrant has been advised that, in the opinion of the
      Commission, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.</div>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb96a3eea05ef4fb3a7491f66536b17ec">

        <tr>
          <td style="width: 45pt; vertical-align: top; font-weight: bold;">ITEM 7.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">EXEMPTION FROM REGISTRATION CLAIMED.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div>Not applicable.</div>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd23dbd1b863f4567b33c67adfa730644">

        <tr>
          <td style="width: 45pt; vertical-align: top; font-weight: bold;">ITEM 8.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">EXHIBITS</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">The following exhibits are filed herewith:</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z0bff084c083f449a8bc984b712b46fce">

        <tr>
          <td style="width: 14.98%; vertical-align: bottom;">
            <div style="font-weight: bold;">Exhibit</div>
            <div style="font-weight: bold;">Number</div>
          </td>
          <td style="width: 84.95%; vertical-align: bottom;">
            <div style="color: rgb(0, 0, 0); font-weight: bold;">Description</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 14.98%; vertical-align: bottom;">&#160;</td>
          <td rowspan="1" style="width: 84.95%; vertical-align: bottom;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 14.98%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1760854/000176085423000005/a2022xex11xnanobiotixxstat.htm">3.1</a></div>
          </td>
          <td style="width: 84.95%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div><font style="color: #000000;">By-laws of the Registrant (English translation) (incorporated herein by reference to Exhibit 1.1 to the </font>Registrant&#8217;s Annual Report on Form 20-F (File No. 333-39777) for the year ended December 31,
              2022)</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 14.98%; vertical-align: middle;">&#160;</td>
          <td rowspan="1" style="width: 84.95%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 14.98%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1760854/000114036120026217/nt10009390x7_ex4-1.htm">4.1</a></div>
          </td>
          <td style="width: 84.95%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div><font style="color: #000000;">Form of Deposit Agreement by and among Nanobiotix S.A. and Citibank, N.A., as depositary, and the Holders and Beneficial Owners of American Depositary Shares issued thereunder (incorporated herein by reference
                to Exhibit 4.1 to the </font>Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-250707))</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 14.98%; vertical-align: middle;">&#160;</td>
          <td rowspan="1" style="width: 84.95%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 14.98%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1760854/000114036120026217/nt10009390x7_ex4-1.htm">4.2</a></div>
          </td>
          <td style="width: 84.95%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">Form of American Depositary Receipt (included in Exhibit 4.1)</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 14.98%; vertical-align: middle;">&#160;</td>
          <td rowspan="1" style="width: 84.95%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 14.98%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);"><a href="brhc20054774_ex5-1.htm">5.1*</a></div>
          </td>
          <td style="width: 84.95%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">Opinion of Jones Day</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 14.98%; vertical-align: middle;">&#160;</td>
          <td rowspan="1" style="width: 84.95%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 14.98%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);"><a href="brhc20054774_ex23-1.htm">23.1*</a></div>
          </td>
          <td style="width: 84.95%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">Consent of Ernst &amp; Young et Autres</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 14.98%; vertical-align: middle;">&#160;</td>
          <td rowspan="1" style="width: 84.95%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 14.98%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);"><a href="brhc20054774_ex5-1.htm">23.2*</a></div>
          </td>
          <td style="width: 84.95%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">Consent of Jones Day (included in Exhibit 5.1)</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 14.98%; vertical-align: middle;">&#160;</td>
          <td rowspan="1" style="width: 84.95%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 14.98%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);"><a href="#POWEROFATTORNEY">24.1*</a></div>
          </td>
          <td style="width: 84.95%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">Power of Attorney of each of the directors of the Registrant and the principal executive, financial and accounting officers of the Registrant (included on the signature page of this Form S-8)</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 14.98%; vertical-align: middle;">&#160;</td>
          <td rowspan="1" style="width: 84.95%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 14.98%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);"><a href="brhc20054774_ex99-1.htm">99.1*</a></div>
          </td>
          <td style="width: 84.95%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">Summary of <font style="font-weight: normal;">2023</font> Free Share Plan</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 14.98%; vertical-align: middle;">&#160;</td>
          <td rowspan="1" style="width: 84.95%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 14.98%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);"><a href="brhc20054774_ex107.htm">107*</a></div>
          </td>
          <td style="width: 84.95%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">Filing Fee Table</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div>* Filed herewith.</div>
    <div> <br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za600e1ebd05b4a149115f8504afaa9a7">

        <tr>
          <td style="width: 45pt; vertical-align: top; font-weight: bold;">ITEM 9.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">UNDERTAKINGS</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="text-align: justify;">1.&#160;&#160; The undersigned Registrant hereby undertakes:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(a)&#160;&#160; To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(i)&#160; &#160; To include any prospectus required by Section 10(a)(3) of the Securities Act;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(ii)&#160;&#160; To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in
      the aggregate, represent a fundamental change in the information set forth in the Registration Statement.&#160; Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would
      not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in
      volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective Registration Statement;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(iii)&#160;&#160; To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the
      Registration Statement;</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-style: italic;">Provided, however,</font> that paragraphs (a)(i) and (a)(ii) do not apply if the information required to be included in a post-effective amendment by those
      paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(b)&#160;&#160; That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities
      offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(c)&#160; &#160; To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">2.&#160;&#160; The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant&#8217;s annual report pursuant to Section 13(a) or Section 15(d) of
      the Exchange Act (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration
      statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">3.&#160;&#160; Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the
      Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such
      liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or
      controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether
      such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; font-weight: bold;">SIGNATURES</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8
      and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Paris, France on June 27, 2023.</div>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z477a496f85334af4a3bb8b6777fb9481">

        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="vertical-align: top;">
            <div style="color: rgb(0, 0, 0); font-weight: bold;">NANOBIOTIX S.A.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 47%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 3%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">By:</div>
          </td>
          <td style="width: 47%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: rgb(0, 0, 0);">/s/ Laurent Levy</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 47%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">Name:&#160; Laurent Levy, Ph.D.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 47%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">Title:&#160; Chairman of the Executive Board</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; font-weight: bold;"><a name="POWEROFATTORNEY"><!--Anchor--></a>POWER OF ATTORNEY</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">We, the undersigned directors, officers and/or authorized representative in the United States of Nanobiotix S.A., hereby severally constitute and appoint Laurent Levy and Bart Van Rhijn, and each of
      them singly, our true and lawful attorneys, with full power to any of them, and to each of them singly, to sign for us and in our names in the capacities indicated below any and all pre-effective and post-effective amendments to this Registration
      Statement on Form S-8, under the Securities Act of 1933, as amended, <font style="color: rgb(0, 0, 0);">in connection with the registration under the Securities Act of 1933, as amended, of equity securities of Nanobiotix S.A., and to file or cause
        to be filed the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys, and each of them, full power and authority to do and perform each and every act
        and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as each of them might or could do in person, and hereby ratifying and confirming all that said attorneys, and each of them, or their
        substitute or substitutes, shall do or cause to be done by virtue of this Power of Attorney.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities indicated on June 27, 2023.</div>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z5ced28840ca242d086fba42a2ca7f8b0">

        <tr>
          <td style="width: 34.96%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: rgb(0, 0, 0); font-weight: bold;">Signature</div>
          </td>
          <td style="width: 5.66%; vertical-align: top;"><br>
          </td>
          <td style="width: 59.38%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Title</div>
          </td>
        </tr>
        <tr>
          <td style="width: 34.96%; vertical-align: top;">&#160;</td>
          <td style="width: 5.66%; vertical-align: top;"><br>
          </td>
          <td style="width: 59.38%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 34.96%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: rgb(0, 0, 0);">/s/ Laurent Levy</div>
          </td>
          <td style="width: 5.66%; vertical-align: top;"><br>
          </td>
          <td style="width: 59.38%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);">Chairman of the Executive Board</div>
          </td>
        </tr>
        <tr>
          <td style="width: 34.96%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">Laurent Levy</div>
          </td>
          <td style="width: 5.66%; vertical-align: top;"><br>
          </td>
          <td style="width: 59.38%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-style: italic;">(Principal Executive Officer)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 34.96%; vertical-align: top;">&#160;</td>
          <td style="width: 5.66%; vertical-align: top;"><br>
          </td>
          <td style="width: 59.38%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 34.96%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: rgb(0, 0, 0);">/s/ Bart Van Rhijn</div>
          </td>
          <td style="width: 5.66%; vertical-align: top;"><br>
          </td>
          <td style="width: 59.38%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);">Chief Financial Officer and Executive Board Member</div>
          </td>
        </tr>
        <tr>
          <td style="width: 34.96%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">Bart Van Rhijn</div>
          </td>
          <td style="width: 5.66%; vertical-align: top;"><br>
          </td>
          <td style="width: 59.38%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-style: italic;">(Principal Financial Officer and Principal Accounting Officer)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 34.96%; vertical-align: top;">&#160;</td>
          <td style="width: 5.66%; vertical-align: top;"><br>
          </td>
          <td style="width: 59.38%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 34.96%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: rgb(0, 0, 0);">/s/ Gary Phillips</div>
          </td>
          <td style="width: 5.66%; vertical-align: top;"><br>
          </td>
          <td style="width: 59.38%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);">Supervisory Board Chairman</div>
          </td>
        </tr>
        <tr>
          <td style="width: 34.96%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">Gary Phillips</div>
          </td>
          <td style="width: 5.66%; vertical-align: top;"><br>
          </td>
          <td style="width: 59.38%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 34.96%; vertical-align: top;">&#160;</td>
          <td style="width: 5.66%; vertical-align: top;"><br>
          </td>
          <td style="width: 59.38%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 34.96%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: rgb(0, 0, 0);"><br>
            </div>
          </td>
          <td style="width: 5.66%; vertical-align: top;"><br>
          </td>
          <td style="width: 59.38%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);">Supervisory Board Vice Chairwoman</div>
          </td>
        </tr>
        <tr>
          <td style="width: 34.96%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0); font-weight: normal;">Anne-Marie Graffin</div>
          </td>
          <td style="width: 5.66%; vertical-align: top;"><br>
          </td>
          <td style="width: 59.38%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 34.96%; vertical-align: top;">&#160;</td>
          <td style="width: 5.66%; vertical-align: top;"><br>
          </td>
          <td style="width: 59.38%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 34.96%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: rgb(0, 0, 0);">/s/ Alain Herrera</div>
          </td>
          <td style="width: 5.66%; vertical-align: top;"><br>
          </td>
          <td style="width: 59.38%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);">Supervisory Board Member</div>
          </td>
        </tr>
        <tr>
          <td style="width: 34.96%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">Alain Herrera</div>
          </td>
          <td style="width: 5.66%; vertical-align: top;"><br>
          </td>
          <td style="width: 59.38%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 34.96%; vertical-align: top;">&#160;</td>
          <td style="width: 5.66%; vertical-align: top;"><br>
          </td>
          <td style="width: 59.38%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 34.96%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: rgb(0, 0, 0);">/s/ Enno Spillner<br>
            </div>
          </td>
          <td style="width: 5.66%; vertical-align: top;"><br>
          </td>
          <td style="width: 59.38%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);">Supervisory Board Member</div>
          </td>
        </tr>
        <tr>
          <td style="width: 34.96%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">Enno Spillner</div>
          </td>
          <td style="width: 5.66%; vertical-align: top;"><br>
          </td>
          <td style="width: 59.38%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; font-weight: bold;">AUTHORIZED REPRESENTATIVE IN THE UNITED STATES</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-8 has been signed by the undersigned as the duly authorized representative in the United
      States of Nanobiotix S.A. in Paris, France on June 27, 2023.</div>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z79f4bd07482b4bc6959f721f293a53bf">

        <tr>
          <td style="width: 50%; vertical-align: top;"><br>
          </td>
          <td colspan="2" style="vertical-align: top;">
            <div style="color: rgb(0, 0, 0); font-weight: bold;">NANOBIOTIX CORPORATION</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;"><br>
          </td>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 47%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;"><br>
          </td>
          <td style="width: 3%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">By:</div>
          </td>
          <td style="width: 47%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: rgb(0, 0, 0);">/s/ Bart Van Rhijn</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;"><br>
          </td>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 47%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">Name:&#160; Bart Van Rhijn</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;"><br>
          </td>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 47%; vertical-align: top;">
            <div style="color: #000000;">Title:&#160; Chief Financial Officer and Authorized</div>
            <div style="color: #000000;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Signatory</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div><br>
    </div>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
</body>
</html>
[{"type": "S-8", "sequence": "1", "filename": "brhc20054774_s-8.htm", "description": "S-8", "secsgml_size_bytes": 49880}]
{"company-data": {"conformed-name": "Nanobiotix S.A.", "cik": "0001760854", "assigned-sic": "2834", "irs-number": "000000000", "state-of-incorporation": "I0", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-272947", "film-number": "231044017"}, "business-address": {"street1": "60 RUE DE WATTIGNIES", "city": "PARIS", "state": "I0", "zip": "75012", "phone": "33140260470"}, "mail-address": {"street1": "60 RUE DE WATTIGNIES", "city": "PARIS", "state": "I0", "zip": "75012"}}
As filed with the Securities and Exchange Commission on June 27, 2023
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
NANOBIOTIX S.A.
(Exact name of registrant as specified in its charter)
France
Not applicable
(State or other jurisdiction of incorporation or organization)
(I.R.S. employer identification No.)
60 rue de Wattignies
75012 Paris, France
(Address of Principal Executive Offices)(Zip Code)
2023 Free Share Plan
(Full title of the plans)
Nanobiotix Corporation
Attn: Bart Van Rhijn
245 Main Street
Cambridge, Massachusetts 02142
+1 617 712 1568
(Name and address of agent for service) (Telephone number, including area code, of agent for service)
Copies to:
Peter E. Devlin
Shoshana E. Litt
Jones Day
250 Vesey Street
New York, New York 10281
+1 212 326 3939
Renaud Bonnet
Jean-Gabriel Griboul
Jones Day
2 rue Saint-Florentin
75001 Paris, France
+33 1 56 59 39 39
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated
      filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☐
Accelerated filer
☒
Non-accelerated filer
☐
Smaller reporting company
☐
Emerging growth company
☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to
        Section 7(a)(2)(B) of the Securities Act. ☐
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
The information specified in Part I of Form S-8 is omitted from this Registration Statement in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the "
Securities Act
") and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the plans covered by this Registration
      Statement as specified by Rule 428(b)(1) under the Securities Act.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
ITEM 3.
INCORPORATION OF DOCUMENTS BY REFERENCE
The following documents filed by Nanobiotix S.A. (the "
Registrant
") with the U.S. Securities and Exchange Commission (the "
Commission
") are incorporated by reference into this Registration Statement:
(a)
the Registrant's Annual Report on Form 20-F (File No. 001-39777) for the year ended December 31, 2022, filed with the Commission pursuant to Section 13
      or 15(d) of the Securities Exchange Act of 1934, as amended (the "
Exchange Act
") on
April 24,
        2023
, which contains audited financial statements for the Registrant's latest fiscal year for which such statements have been filed;
(b)
the Registrant's Reports on Form 6-K (File No. 001-39777) that are furnished to the Commission and that are identified in such form as being incorporated
      by reference, since the end of the fiscal year covered by the Registrant's Annual Report on Form 20-F referred to in (a) above; and
(c)
the descriptions of the Registrant's American Depositary Shares and Ordinary Shares contained in the Registrant's Registration Statement on Form 8-A
      filed with the Commission on
December 8, 2020
(File No. 001-39777) under the Exchange Act, including any amendment or report filed for the
      purpose of updating such description, including the description of the Registrant's securities included as
Exhibit 2.3
to the
      Registrant's Annual Report on Form 20-F filed with the Commission on April 24, 2023.
All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior
      to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all such securities then remaining unsold, shall be deemed to be incorporated by
      reference herein and to be a part of this Registration Statement from the date of filing of such reports and documents. Any statement contained in this Registration Statement, in an amendment hereto or in a document incorporated or deemed to be
      incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed amendment to this Registration Statement or in any
      document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this
      Registration Statement.
Information subsequently furnished on Form 6-K shall not be deemed incorporated herein by reference unless such Form 6-K expressly provides to the contrary.
ITEM 4.
DESCRIPTION OF SECURITIES
Not applicable.
ITEM 5.
INTERESTS OF NAMED EXPERTS AND COUNSEL
Not applicable.
ITEM 6.
INDEMNIFICATION OF DIRECTORS AND OFFICERS
Under French law, provisions in the By-laws that limit the liability of directors and officers are ineffective. However, French law allows
sociétés anonymes
to contract for and
      maintain liability insurance against civil liabilities incurred by any of their directors and officers involved in a third-party action,
provided
that they acted in good faith and within their capacities as
      directors or officers of the company. Criminal liability cannot be indemnified under French law, whether directly by the company or through liability insurance. Such rules apply to executive and supervisory board members.
The Registrant has obtained and maintains customary liability insurance coverage for our supervisory board members and executive board members, including insurance against liability under the Securities Act.
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to the Registrant's directors, officers and controlling persons, the Registrant has been advised that, in the opinion of the
      Commission, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.
ITEM 7.
EXEMPTION FROM REGISTRATION CLAIMED.
Not applicable.
ITEM 8.
EXHIBITS
The following exhibits are filed herewith:
Exhibit
Number
Description
3.1
By-laws of the Registrant (English translation) (incorporated herein by reference to Exhibit 1.1 to the
Registrant's Annual Report on Form 20-F (File No. 333-39777) for the year ended December 31,
              2022)
4.1
Form of Deposit Agreement by and among Nanobiotix S.A. and Citibank, N.A., as depositary, and the Holders and Beneficial Owners of American Depositary Shares issued thereunder (incorporated herein by reference
                to Exhibit 4.1 to the
Registrant's Registration Statement on Form F-1 (File No. 333-250707))
4.2
Form of American Depositary Receipt (included in Exhibit 4.1)
5.1*
Opinion of Jones Day
23.1*
Consent of Ernst & Young et Autres
23.2*
Consent of Jones Day (included in Exhibit 5.1)
24.1*
Power of Attorney of each of the directors of the Registrant and the principal executive, financial and accounting officers of the Registrant (included on the signature page of this Form S-8)
99.1*
Summary of
2023
Free Share Plan
107*
Filing Fee Table
* Filed herewith.
ITEM 9.
UNDERTAKINGS
1.   The undersigned Registrant hereby undertakes:
(a)   To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
(i)    To include any prospectus required by Section 10(a)(3) of the Securities Act;
(ii)   To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in
      the aggregate, represent a fundamental change in the information set forth in the Registration Statement.  Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would
      not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in
      volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective Registration Statement;
(iii)   To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the
      Registration Statement;
Provided, however,
that paragraphs (a)(i) and (a)(ii) do not apply if the information required to be included in a post-effective amendment by those
      paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.
(b)   That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities
      offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(c)    To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
2.   The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant's annual report pursuant to Section 13(a) or Section 15(d) of
      the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration
      statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
3.   Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the
      Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such
      liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or
      controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether
      such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8
      and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Paris, France on June 27, 2023.
NANOBIOTIX S.A.
By:
/s/ Laurent Levy
Name:  Laurent Levy, Ph.D.
Title:  Chairman of the Executive Board
POWER OF ATTORNEY
We, the undersigned directors, officers and/or authorized representative in the United States of Nanobiotix S.A., hereby severally constitute and appoint Laurent Levy and Bart Van Rhijn, and each of
      them singly, our true and lawful attorneys, with full power to any of them, and to each of them singly, to sign for us and in our names in the capacities indicated below any and all pre-effective and post-effective amendments to this Registration
      Statement on Form S-8, under the Securities Act of 1933, as amended,
in connection with the registration under the Securities Act of 1933, as amended, of equity securities of Nanobiotix S.A., and to file or cause
        to be filed the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys, and each of them, full power and authority to do and perform each and every act
        and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as each of them might or could do in person, and hereby ratifying and confirming all that said attorneys, and each of them, or their
        substitute or substitutes, shall do or cause to be done by virtue of this Power of Attorney.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities indicated on June 27, 2023.
Signature
Title
/s/ Laurent Levy
Chairman of the Executive Board
Laurent Levy
(Principal Executive Officer)
/s/ Bart Van Rhijn
Chief Financial Officer and Executive Board Member
Bart Van Rhijn
(Principal Financial Officer and Principal Accounting Officer)
/s/ Gary Phillips
Supervisory Board Chairman
Gary Phillips
Supervisory Board Vice Chairwoman
Anne-Marie Graffin
/s/ Alain Herrera
Supervisory Board Member
Alain Herrera
/s/ Enno Spillner
Supervisory Board Member
Enno Spillner
AUTHORIZED REPRESENTATIVE IN THE UNITED STATES
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-8 has been signed by the undersigned as the duly authorized representative in the United
      States of Nanobiotix S.A. in Paris, France on June 27, 2023.
NANOBIOTIX CORPORATION
By:
/s/ Bart Van Rhijn
Name:  Bart Van Rhijn
Title:  Chief Financial Officer and Authorized
Signatory